PRODUCTION AND BIOSAFETY TESTING OF A RETROVIRAL VECTOR SUPERNATANTFOR GENE THERAPY OF FABRY DISEASE NIH GUIDE, Volume 25, Number 12, April 19, 1996 RFP AVAILABLE: NIH-NINDS-96-06 P.T. 34 Keywords: Biological Resources Neurological Disorders National Institute of Neurological Disorders and Stroke The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH),will solicit proposals for the production of 30 liters (10 liters each year) of high-titer retroviral supernatant solutions under GMP conditions, biosafety testing, and delivery for the transduction of stem and progenitor cells for patients with Fabry disease. Offerors are required to have a facility that has been inspected by the FDA and is in compliance with established current Good Manufacturing Practices (GMP) and current Good Laboratory Practices (GLP). Offerors must have personnel on staff with established experience in the production of retroviruses under GMP conditions. It is anticipated that one contract will be awarded for a maximum period of three years. Payment will be on a cost-reimbursement type basis. INQUIRIES This is not a Request for Proposals. Request for Proposals (RFP) No. NIH-NINDS-96-06 was issued on April 15, 1996 with responses due approximately forty-five days thereafter. All responsible sources may submit a proposal that will be considered by the Government. Requests for the RFP must cite the RFP number and include two self-addressed mailing labels. Written or FAX requests may be submitted to: Raina Cervantes Contracts Management Branch National Institute of Neurological Disorders and Stroke 7550 Wisconsin Avenue, Room 901 - MSC 9190 Bethesda, MD 20892-9190 FAX: (301) 402-4225 ATTN: RFP NIH-NINDS-96-06 .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||